Pharmacodynamic considerations in oral cephalosporin therapy: Implications for selection and effectiveness

Infectious Diseases in Clinical Practice

Volumn 7, Issue SUPPL. 2, 1998, Pages

  Nicolau, David P ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFRADINE; CEFTIBUTEN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; LORACARBEF; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN;

ANIMAL MODEL; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CONFERENCE PAPER; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0031843761     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199808002-00004     Document Type: Conference Paper

References (13)

1. Nicolau DP, Quintiliani R, Nightingale CH. Antibiotic kinetics and dynamics for the clinician. Med Clin North Am 1995;79:477-95.
2. Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991:91(6A Suppl):45S-50S.
3. Begg EJ, Peddie BA, Chambers ST, et al. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother 1992;29:427-33.
4. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of pseudomonas sepsis. Antimicrob Agents Chemother 1993;37 483-90.
5. Craig WA, Ebert SC Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991;74(Suppl):63-70.
6. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics. applications to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-26.
7. Vogelman B, Gundmundsson S, Legget J, et al. Correlation of antimicrobial pharmacokinetic parameters with efficacy in an animal model J Infect Dis 1988,158. 831-47.
8. Garrison MW, Malone CL, Eiland JE. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996;40.1545-7.
9. Onyeji CO, Nicolau DP, Nightingale CH. et al Optimal duration of time above the minimum inhibitory concentrations of ceftibuten and cefaclor in experimental abdominal infections. Antimicrob Agents Chemother 1994; 38:1112-7
10. Knudsen JD, Frimodt-Moller N. Espersen F. Experimental Streptococcus pneumoniae infection in mice for studying correlation in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob Agents Chemother 1995; 39:1253-8.
11. Bodey GP, Ketchel SJ, Rodriquez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-11.
12. Schentag JJ, Smith IL, Swanson DJ, et al. Role of dual individualization with cefmenoxime. Am J Med 1984;77(6A Suppl):43-50.
13. Zeisler JA, McCarthy JD, Richelieu WA, et al. Cefuroxime by continuous infusion: a new standard of care? Infect Med 1992;9:54-60.